TABLE 4.

Efficacy during treatment with crizotinib

ORR in patients with at least one radiological evaluation (n = 60)	60% (1CR + 35PR) (95% CI: 46.5%–72.4%)
ORR in patients with target lesions (n = 42)	85.7% (1CR + 35PR) (95% CI: 71.5%–94.6%)
Median maximum tumor reduction rate (n = 42)	56% (range: −40%, 100%)
Intracranial ORR in patient with CNS metastases following at least one radiological evaluation (n = 9)	22.2% (2PR) (95% CI: 2.8%–60.0%)
Intracranial ORR in patient with measurable CNS lesions (n = 5)	40% (2PR) (95% CI: 5.3%–85.3%)
Improvement in CNS related symptoms (n = 1)
Significant improvement	0
Moderate improvement	0
No improvement	1
Deterioration	0